HUBUNGAN ANTARA STATUS RESEPTOR ESTROGEN, RESEPTOR PROGESTERON DAN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 DENGAN DERAJAT KEGANASAN KARSINOMA PAYUDARA INVASIF

Muhartono Muhartono, Soraya Ramanisa, Hanna Mutiara, Ria Janita Riduan

Abstract

Karsinoma payudara invasif (KPI) merupakan keganasan yang berasal dari epitel saluran kelenjar susu dan menginvasi jaringan sekitarnya. Pemeriksaan patologi anatomi biasanya menyertakan derajat keganasan (DKg) dan dilanjutkan dengan pemeriksaan imunohistokimia estrogen receptor (ER), progesterone receptor (PR) dan human epidermal growth factor receptor 2 (HER2) untuk menentukan terapi dan memperkirakan prognosis. Penelitian ini bertujuan untuk mengetahui hubungan status ER, PR, HER–2 dengan DKg pada KPI. Subjek penelitian yang digunakan adalah pasien KPI yang telah diperiksa DKg, status ER, PR dan HER–2 pada tahun 2014–2015 di RSUD Abdoel Moeloek Bandar Lampung. Hasil penelitian menunjukkan DKg low grade sebanyak 13 pasien (24,1%), high grade sebanyak 41 pasien (75,9%), status ER‒ sebanyak 32 pasien (50,3%), ER+ sebanyak 22 pasien (40,7%), PR‒ sebanyak 32 pasien (59,3%), PR+ sebanyak 22 (40,7%) dan HER2‒ sebanyak 33 pasien (61,1%), HER2+ sebanyak 21 pasien (38,9%). Hasil uji Chi‒Square antara ER dengan DKg nilai p=0,001, antara PR dengan DKg nilai p=0,002, antara HER2 dengan DKg nilai p=0,53. Simpulan, terdapat hubungan antara estrogen receptor dan progesterone receptor dengan derajat keganasan pada karsinoma duktal invasif.

Keywords

karsinoma payudara invasif; derajat keganasan; ER; PR; HER2

Full Text:

PDF

References

American Cancer Society. 2015. Cancer Facts & Figures 2015. Atlanta: American Cancer Society.

Suryaningsih E, Sukosa B. 2009. Kupas Tuntas Kanker Payudara. Yogyakarta: Paradigma Indonesia.

Ibrahim R. 2008. Penanganan Kanker Stadium Lanjut. Jakarta: PT. Rineka Cipta.

Davey P. 2006. Medicine At a Glance. Oxford: Blackwell Publishing Ltd.

Aryandono T, Harijadi, Soeripto. 2006. Hormone Receptor Status of Operable Breast Cancers in Indonesia: Correlation with Other Prognostic Factors and Survival. Asian Pacific J Cancer Prev. 7(1): 321–324.

Gray MJ, Gallick GE. 2010. The Role of Oncogene Activation in Tumor Progression. Mechanisms of Oncogenesis. USA: Springer.

Grushko TA, Olopade OI. 2008. Genetic markers in breast tumors with hereditary predisposition. Principle of Molecular Oncology. 3rd Edition. New Jersey: Humana Press.

Ayadi L, Khabir A, Amouri H, Karray S, Dammak A, Guermazi M., et al. 2008. Correlation of HER–2 over–expression with clinico–pathological parameters in Tunisian breast carcinoma. World J Surg Oncol. 6(1):1–8.

Rasjidi I, Hartanto A. 2009. Kanker Payudara. Dalam: Deteksi Dini dan Pencegahan Kanker Pada Wanita. Jakarta: Sagung Seto.

Windarti I. 2014. Characteristic of Breast Cancer In Young Women in H. Abdul Moeloek Hospital Bandar Lampung. JUKE. 4(7):131–135.

Sadhana, Udadi. 2006. Kanker Payudara Wanita: Ekspresi Reseptor Estrogen, Reseptor Progesteron, dan HER–2. Diakses pada tanggal 10 November 2015 dari http://www.m3undip.org.

Baziad A, Santoso BI, Josoprawiro MJ. 1997. Terapi hormone pengganti (THP) dan sindroma urogenital Dalam: Baziad A. Affandi B. Panduan Menopause. Edisi pertama. Jakarta: POGI/PERMI.

Hussain GA, Adhraei MA, Kasim A. 2011. Correlations of Hormone Receptors (ER and PR), Her–2/neu and p53 Expression in Breast Ductal Carcinoma Among Yemeni Woman. The Open Cancer Immunolog J. 4(1): 1–9.

Rosai J. 2004. Breast. Dalam: Rosai and Ackerman’s Surgical Pathology, 10th ed. Philadelphia: Elsevier.

Lari SA, Kuerer HM. 2011. Review: biological markers in DCIS and risk of breast recurrence: a systemetic review. J Cancer. 24(2):232–61.

Chabner BA, Longo DL. 2011. Cancer Chemotherapy and Biotherapy: Principles and Practice. Philadelphia: Lippincott.

Rahman A, Sampepajung D, Hamdani W. 2011. Hubungan Ekspresi HER–2/neu dan Hormonal Reseptor dengan Grading Histopatologi pada Penderita Kanker Payudara Wanita Usia Muda [skripsi]. Makassar: Universitas Hasanuddin.

Dunnwald LK, Rossing MA, Li CI. 2007. Hormone Receptor Status, Tumor Characteristics, and Prognosis: A Prospective Cohort of Breast Cancer Patients. Breast Cancer Res. 9(1):1–10.

Faheem M, Mahmood H, Khurram M, Qasim U, Irfan J. 2012. Estrogen Receptor, Progesteron Receptor, and Her–2 Neu Positivity and It’s Association with Tumour Characteristics and Menopausal Status in Breast Cancer Cohort From Northern Pakistan. Ecancer Med Science. 6(1):283.

Ratnatunga N, Liyanapathirana L. 2007. Hormone receptor expression and Her–2/neu amplification in breast carcinoma in a cohort of Sri Lankans. Ceylon Med J. 52(4): 133–6.

Noorasmaliza, Siti A, Reena, Meor Z, Wan A, Mohan N, et al. 2014. Estrogen Receptor– Negative Breast Ductal Carcinoma: Clinicopathological Features and Mib–1 (Ki–67) Proliferative Index Association. PlosONE.9(2):e89172.

Yager JD, Davidson NE. 2006. Mechanisms of Disease, Estrogen Carcinogenesis in Breast Cancer. New England J Med; 354(3):271–79.

Ellis IO, Schnitt SJ, Sastre GX. 2003. Invasive Breast Carcinoma in World Health Organization Classification of Tumors Pathology & Genetics Tumors of the Breast and Female Genital Organs. Lyon: IARC Press.

Mote P, Bartow S, Tran N, Clarke C. 2002. Loss of Co–ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res Treat. 72(2): 163–72.

Malley O, Bert W, Birnbaumer L. 1978. Receptors and Hormone Action. New York: Academic Press.

Homaei S, Ghavam N, Shafiri N, Taghizadeh K, Torshizi S, Ghafarzadegan K. 2006. Evaluation of the relationship between human epidermal growth factor receptor–2/neu (c–erb–2) amplification and pathologic grading in patients with breast cancer. Saudi Med J. 27(12):1810–4.

Kumar V, Cotran RS, Robbins SL. 2007. Buku Ajar Patologi Edisi ke–7. Jakarta: EGC.

Refbacks

  • There are currently no refbacks.
';